ALK and non-small cell lung carcinoma: Efficacy ranking analysis for the three ALK inhibitors—brigatinib, alectinib, and crizotinib—revealed that alectinib ranked the highest in the overall ALK-p NSCLC patient population, whereas brigatinib ranked the highest in patients with ALK-p advanced NSCLC with CNS metastasis.